🇺🇸 FDA
Pipeline program

18F-92

MRCTA, ECFAH of FMU [2021]130

Phase 2 small_molecule active

Quick answer

18F-92 for Alzheimer's Disease is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Alzheimer's Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials